To evaluate the effectiveness of enlicitide in lowering LDL cholesterol in high-risk patients despite statin use.
Key Findings:
Enlicitide users experienced up to a 60% reduction in LDL cholesterol over six months.
The cholesterol-lowering effect persisted with only a slight decrease over one year.
No safety differences were observed between enlicitide and placebo groups.
Interpretation:
Enlicitide may provide a significant alternative to current cholesterol-lowering treatments, particularly for patients who do not achieve desired LDL levels with statins alone.
Limitations:
The long-term effects on heart attack and stroke rates are not yet established.
The pill must be taken on an empty stomach.
Conclusion:
If approved by the FDA, enlicitide could offer a more convenient oral option for managing high cholesterol in patients at risk for heart disease.
